BOSTON SCIENTIFIC CORP (BSX) Factsheet

BOSTON SCIENTIFIC CORP (BSX) Stock Analysis

Analysis from 10-Q filed 2026-11-02. Data as of Q3 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 10.3%. FCF margin 15.8%. D/E 0.5x. Source: 10-Q filed 2026-11-02.

Metric	Value	Context
ROIC	10.3%	Near cost of capital
FCF Margin	15.8%	Strong cash generation
Debt/Equity	0.5x	Conservative leverage

ROIC 10.3% — Top 25% of sector peers. FCF margin 15.8% — Top 25%.

Explore BOSTON SCIENTIFIC CORP: Earnings History | Overview

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for BSX: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: BOSTON SCIENTIFIC CORP earns 10.3% ROIC, Top 25% in Healthcare

ROIC TTM 10.3%, sector median -6.9%, Top 25%. DuPont: NOPAT margin 17.8% × asset turnover 0.5x. Gross margin 69.1%. Operating margin 18.7%. Source: 10-Q filed 2026-11-02.

Metric	BSX	Rating	Context
Return on Invested Capital (ROIC)	10.3%	Adequate	Above sector median of -6.9%
Return on Equity (ROE)	14.1%	Adequate	Moderate equity returns
Gross Margin	69.1%	Excellent	Strong pricing power
Operating Margin	18.7%	Good	Efficient operations

---

Cash Flow: BOSTON SCIENTIFIC CORP generates $3.3B FCF at 15.8% margin, positive NaN/8 quarters

FCF TTM $3.3B. FCF margin 15.8%, Top 25%. OCF/Net income 1.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-11-02.

Metric	BSX	Rating	Context
Free Cash Flow Margin	15.8%	Good	Excellent cash conversion
Free Cash Flow (TTM)	$3.3B	Good	Positive cash generation
OCF/Net Income	1.2x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: BOSTON SCIENTIFIC CORP at 0.5x leverage, 10.5x interest coverage

Debt/Equity 0.5x. Total debt $12.0B, cash & investments $609.0M. Interest coverage 10.5x. Source: 10-Q filed 2026-11-02.

Metric	BSX	Rating	Context
Debt to Equity	0.5x	Good	Conservative capital structure
Net Cash Position	$-11.3B	Warning	Net debt position
Interest Coverage	10.5x	Excellent	Comfortable debt service

---

Valuation: BOSTON SCIENTIFIC CORP trades at 18.3x earnings

P/E 18.3x. EV/Sales 3.6x. FCF yield 5.2%. Source: 10-Q filed 2026-11-02.

Metric	BSX	Rating	Context
P/E Ratio	18.3x	Adequate	Reasonable valuation
EV/Sales	3.6x	Good	Growth premium priced in
FCF Yield	5.2%	Good	Attractive cash return

---

Capital Allocation: BOSTON SCIENTIFIC CORP returns 0.0% shareholder yield, reducing shares 2.2% YoY

Total shareholder yield 0.0%. Share count -2.2% YoY. Capital returned $0 TTM. Source: 10-Q filed 2026-11-02.

Metric	BSX	Rating	Context
Total Shareholder Yield	0.0%	Warning	Dividend + buyback yield combined
Share Count Change (YoY)	-2.2%	Good	Net share reduction (accretive)
Total Capital Returned (TTM)	$0	Adequate	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	10.3%	Top 25%	-
Free Cash Flow Margin	15.8%	Top 25%	5.2x above
Gross Margin	69.1%	Top 50%	1.1x above
Operating Margin	18.7%	Top 25%	-
Return on Equity (ROE)	14.1%	Top 50%	-
P/E Ratio	18.3x	N/A	-

---

Financial Scorecard

Metric	BSX	Rating	Sector Context
Return on Invested Capital (ROIC)	10.3%	Adequate	Top 25% of sector (median: -6.9%)
Free Cash Flow Margin	15.8%	Good	Top 25% of sector (median: 3.0%)
Gross Margin	69.1%	Excellent	Top 50% of sector (median: 63.8%)
Debt to Equity Ratio	46.6%	Good	Moderate leverage
P/E Ratio (Price-to-Earnings)	18.3x	Adequate	Fair value
Free Cash Flow Yield	5.2%	Good	Solid cash yield

---

Frequently Asked Questions

Q: What is BOSTON SCIENTIFIC CORP's Return on Invested Capital (ROIC)?

BOSTON SCIENTIFIC CORP (BSX) has a trailing twelve-month Return on Invested Capital (ROIC) of 10.3%. The 8-quarter median ROIC is 9.1% with a improving trend. Sector median -6.9%. Source: 10-Q filed 2026-11-02.

Q: What is BOSTON SCIENTIFIC CORP's Free Cash Flow Margin?

BOSTON SCIENTIFIC CORP (BSX) has a free cash flow margin of 15.8%, generating $3.3 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-11-02.

Q: What is BOSTON SCIENTIFIC CORP's P/E ratio and how does it compare to peers?

BOSTON SCIENTIFIC CORP (BSX) trades at a P/E ratio of 18.3x, which is above the sector median of N/A. EV/Sales 3.6x. FCF yield 5.2%. Source: 10-Q filed 2026-11-02.

Q: What is BOSTON SCIENTIFIC CORP's revenue and earnings growth?

BOSTON SCIENTIFIC CORP (BSX) grew revenue by 8.9% year-over-year. EPS +26.6% YoY. Source: 10-Q filed 2026-11-02.

Q: How does BOSTON SCIENTIFIC CORP compare to competitors in Healthcare?

Compared to other companies in Healthcare, BOSTON SCIENTIFIC CORP (BSX) shows: ROIC 10.3%, sector median -6.9% (Top 25%). FCF margin 15.8%, sector median 3.0% (Top 25%). Gross margin 69.1%, 5.3pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with BOSTON SCIENTIFIC CORP?

No quantitative warning flags fired for BOSTON SCIENTIFIC CORP (BSX) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2026-11-02.

---

Data Source: Data sourced from 10-Q filed 2026-11-02. TTM metrics as of Q3 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.